Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MediBIC to Codevelop Anticancer Agent with Threshold Pharmaceuticals
February 7, 2005
- BUSINESS NEWS IN BRIEF
February 7, 2005
- Strong Demand for Microdose Clinical Studies
February 7, 2005
- BUSINESS SEMINAR
February 7, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 7, 2005
- WEBSITE NEWS
February 7, 2005
- Press Seminar
February 7, 2005
- PMDA Publishes Results of Survey on Social Expectations for R&D
January 31, 2005
-
January 31, 2005
- Use of Iressa in Japan to Continue as at Present: Korosho
January 31, 2005
- JSMI to Continue Raising Awareness of Self-medication in 2005
January 31, 2005
- Nippon Kayaku: Half-year Drug Sales Down 8.7% to \18.7 Bil.
January 31, 2005
- Sales of Foods for Health & Beauty Care Rose 9% in 2004: Fuji-Keizai
January 31, 2005
- Number of Births in 2004 Lowest Ever Recorded: Korosho
January 31, 2005
- Yamanouchi, RIKEN Elucidate Genetic Network of Biological Clock
January 31, 2005
- REGULATORY NEWS IN BRIEF
January 31, 2005
- DIAGNOSTIC NEWS IN BRIEF
January 31, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
January 31, 2005
- New Medical Devices GLP to Be Announced Shortly
January 31, 2005
- Meiji Seika to Reinforce Pharma Business in China
January 31, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…